Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.

A compound represented by formula (I) is provided, wherein in formula (I), R.sub.1 and R.sub.2 each independently represents hydrogen, OR.sub.3 or SR.sub.4, at least one of R.sub.1 and R.sub.2 is OR.sub.3 or SR.sub.4, and R.sub.3 and R.sub.4 are independently a C.sub.1 to C.sub.10 alkyl group, such that the C.sub.1 to C.sub.10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of OH, NH.sub.2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents.

##STR00001##

A compound represented by formula (I) is provided, wherein in formula (I), R.sub.1 and R.sub.2 each independently represents hydrogen, OR.sub.3 or SR.sub.4, at least one of R.sub.1 and R.sub.2 is OR.sub.3 or SR.sub.4, and R.sub.3 and R.sub.4 are independently a C.sub.1 to C.sub.10 alkyl group, such that the C.sub.1 to C.sub.10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of OH, NH.sub.2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents. ##STR00001##

The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.

Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

The present invention provides a stabilized form of Tetrofosmin, which is stable at room temperature as well as in contact with oxygen, and a non-radioactive kit containing a stabilized form of Tetrofosmin for the preparation of a radiopharmaceutical composition in the field of diagnostic radiopharmaceuticals, especially for myocardial perfusion studies in patients with coronary artery diseases and in oncology.

Radioimaging methods, devices and radiopharmaceuticals therefor.

The present invention relates to a dual-mode probe for detecting of hydrogen sulfide and use thereof and, more specifically to a dual-mode probe that has excellent blood-brain barrier permeability and is capable of fluorescence and nuclear imaging and a use thereof for detecting hydrogen sulfide.